Antibody-drug conjugates therapy for triple-negative breast cancer: a systematic review and meta-analysis
In brief
Antibody-drug conjugates cut progression or death by about half in triple-negative breast cancer
In a meta-analysis of six studies involving 2,479 patients, antibody-drug conjugates were linked to about half the rate of progression or death and a 40% lower rate of death than conventional chemotherapy. Severe side effects were not significantly more frequent, but the evidence includes one exploratory subgroup analysis, so further trials are needed to confirm the results.
- Journal
- Frontiers in medicine (Q1)
- Published
- 26 October 2026
- Study design
- Systematic review / meta-analysis of RCTs
- Evidence level
- Level 1, High (CEBM 1a)
- Authors
- Ke Wan, Mengxin Liu
- PMID
- 43005154
- DOI
- 10.3389/fmed.2026.1975216
Why clinicians should know about it
- Picked for Oncology and Radiation Oncology (paper of the day, 11 November 2026): ADCs improved OS (HR 0.60) and PFS (HR 0.48) without
Abstract
PURPOSE: This systematic review and meta-analysis aimed to compare the efficacy and safety of antibody-drug conjugates (ADCs) vs. conventional chemotherapy in patients with triple-negative breast cancer (TNBC) and to provide evidence for clinical decision-making and guideline development. METHODS: We systematically searched PubMed, Embase, and Cochrane Library and extracted data including hazard ratio (HR) and 95% confidence interval (CI) for progression-free survival (PFS) and overall survival (OS), odds ratio (OR) for safety, and objective response rate (ORR). RESULTS: This study ultimately included 6 articles (5 dedicated RCTs for TNBC and 1 exploratory analysis of an HR-negative/HER2-low subgroup from the DESTINY-Breast04 trial), including 2,479 patients (1,256 patients in ADCs treatment and 1,223 patients in conventional chemotherapy). HR for PFS was 0.48 [95% CI (0.38, 0.61), P = 0.001], and HR for OS was 0.60 [95% CI (0.46, 0.79), P = 0.027]. OR for incidence of all adverse events (AEs) was 1.05 [95% CI (0.86,1.29), P = 0.901], and OR for incidence of grade ≥ 3 AEs was 1.11 [95% CI (0.88, 1.42), P = 0.984]. The pooled results demonstrated that ADCs significantly improved OS and PFS, while showing no significant increase in overall AEs or grade ≥ 3 AEs compared to control. CONCLUSION: This study suggests that ADCs significantly improve OS and PFS without significantly increasing grade ≥ 3 AEs compared to conventional chemotherapy in TNBC, providing support for clinical decision-making and guideline development. These findings may inform future head-to-head trials, optimization of ADC-based combination regimens, and biomarker-guided precision treatment. As clinical data on novel ADCs continue to accumulate, these conclusions may be further validated and extended.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.